We will expand our current retrospective cohort study to determine the
effect of molecular and histologic factors on breast cancer risk in women
with non-invasive breast disease. The study cohort will consist of 12,670
women with non-invasive breast disease diagnosed at our study hospitals
between 1959 and 1991. Paraffin embedded tissue from their initial breast
biopsies is available on these patients. To date, follow-up has been
obtained on all patients biopsied before 1987. Follow-up to determine
breast cancer diagnosis and other epidemiologic risk factors will be
updated and extended through review of hospital and tumor registry records
as well as interviews with these patients or their next-of-kin. We will
conduct a series of nested case-control studies on these women.
Approximately 455 cohort members will develop invasive breast cancer
during follow-up. These women will be our case patients. Two controls
will be selected for each case matched on entry histology, age at biopsy
and year of biopsy. Our major goals are to determine the influence of
various molecular factors on the breast cancer risk associated with
different types on benign breast disease. These include abnormal
expression or regulation of the extracellular matrix-degrading enzyme
matrilysin, microsatellite instability and loss of heterozygosity in
benign tumors, and several markers of intercellular adhesion, cell
proliferation and angiogenesis. PCR methods will be used to determine
microsatellite instability and loss of heterozygosity.
Immunohistochemical and in situ hybridization methods will be used to
study matrilysin and other proteins. Conditional logistic regression
analysis will be used to assess the individual and combined effects of
molecular, histologic and epidemiologic variables on breast cancer risk.
This project will expand our repository of paraffin embedded breast cancer
tissue on a large cohort of women with known outcome. It will permit the
combination of modern methods in molecular biology, pathology and
epidemiology to assess potentially powerful new markers of breast cancer
prognosis, and may lead to important advances in the prevention and
treatment of this disease.
Error Notice
The database may currently be offline for maintenance and should be operational soon. If not, we have been notified of this error and will be reviewing it shortly.
We apologize for the inconvenience.
- The DCCPS Team.